A condition, known commonly as "black urine disease" or Alkaptonuria is a rare genetic disorder involving protein metabolism, and it has its root in the mutation of the homogentisate 1,2-dioxygenase gene, which in turn causes homogentisic acid accumulation in the body. The appearance of dark urine after exposure to air is due to this kind of accumulation; however, a variety of symptoms can be expected, such as joint stiffness, changes in pigmentation, and other long-term health complications. Although the prevalence has been estimated to be between 1 in 250,000 and 1 in 1 million people in the United States, its effects are indeed high on those affected.

Alkaptonuria is an autosomal recessive disease, meaning that the child must inherit a defective copy of the HGD gene from both parents. If both parents are carriers, their offspring have a 25% chance of inheriting two faulty genes and developing alkaptonuria. The condition is genetic but is often not diagnosed for years because it progresses slowly and its early symptoms appear to be harmless.

Symptoms of Alkaptonuria

The most characteristic and common initial symptom of alkaptonuria is dark urine. The reason for this is due to the fact that excess HGA is excreted in the urine and upon oxidation in the presence of air, it gives the urine a brown or black color. Though it is often considered cosmetic, the long-term accumulation of HGA within the connective tissues produces more complicated health problems.

Progressive joint pain and stiffness: The accumulation of HGA in cartilage leads to early-onset osteoarthritis, making movement increasingly difficult over time.

Skin and eye pigmentation changes: Affected individuals may develop bluish or grayish discoloration of the sclera (white part of the eye) and the skin, particularly in areas exposed to friction.

Cardiovascular and respiratory problems: With age, HGA accumulation can lead to valve calcifications in the heart and stiffening of connective tissues in the respiratory tract, which can cause problems in middle and old age.

Decreased mobility and spinal problems: The spine may become stiff and painful due to chronic cartilage degeneration.

These symptoms usually begin to manifest during adulthood, leading to severe complications in a person's 40s or 50s and significantly affecting the quality of their life.

How is Alkaptonuria Diagnosed?

Because of its rarity, alkaptonuria is often mistaken or overlooked early in life. However, there are several ways to confirm the condition:

Urine Testing: The gold standard in the diagnosis is the testing of urine samples for high levels of homogentisic acid via gas chromatography. In case of oxidation, which changes the color of urine to black, it is indicative of alkaptonuria.

Genetic Testing: Confirmatory genetic testing reveals mutations of the HGD gene to diagnose the condition conclusively.

Blood Tests: High levels of HGA in the blood can be used as further evidence.

Imaging Studies: X-rays and MRIs will expose cartilage and joint damage characteristic of alkaptonuria.

Management of Alkaptonuria: Is There A Cure?

At present, there is no cure for alkaptonuria; however, various treatment approaches can reduce its symptoms and slow the disease's progress:

Nitisinone Therapy: Nitisinone is a drug that inhibits the production of HGA. It has been shown to reduce HGA levels and slow tissue damage. However, it needs to be taken under close medical supervision because of potential side effects.

Low-Protein Diet: Since HGA is a byproduct of protein metabolism, reducing protein intake—especially foods rich in tyrosine and phenylalanine—may help decrease HGA production.

Pain Management: OTC pain relievers and anti-inflammatory medications can be used to relieve joint pain and stiffness.

Physical Therapy: Exercise regularly, as it may improve mobility and strengthen muscles, thus reducing strain on affected joints.

Surgical Interventions: Most people with alkaptonuria develop severe osteoarthritis necessitating joint replacement in their old age. Also, some may require heart valve replacement surgery if cardiovascular complications develop.

Life with Alkaptonuria

Although alkaptonuria is not fatal, it severely affects the quality of life. The progressive deterioration of the joints and associated symptoms can make everyday activities difficult, requiring lifestyle changes and medical interventions. The disease may cause premature aging of the joints, requiring walking aids and mobility assistance earlier than expected.

Ongoing research will continue to work on improving the treatment options by focusing on gene therapy and alternative enzyme replacement therapies. However, because of its rarity, the clinical trials and research remain sparse.

As genetic research advances, more hope for better management and possible curative approaches for alkaptonuria exists. Scientists are searching extensively for enzyme replacement therapies and innovative drugs that can target the root cause of the disorder. Being aware and being diagnosed early helps individuals better their condition and ultimately have better long-term health outcomes.

Alkaptonuria is a striking example of how one gene mutation can have widespread effects on the body. Though still a rare and often misunderstood condition, growing awareness and advances in treatment are paving the way for better care. If you or a loved one suspect symptoms of alkaptonuria, it is essential to seek early diagnosis and medical guidance to manage the disease effectively and preserve quality of life.

A UK woman has claimed that Wegovy and Mounjaro, the blockbuster GLP-1 weight-loss drugs from Novo Nordisk and Eli Lilly, did not help her lose much weight despite more than a year of treatment.

Karen Lay, 56, from Essex, spent £4,000 on the medications, hoping they would help her slim down from 16 stone (224 pounds). However, after 15 months, she lost less than a stone, despite eating very little.

Lay now says the injections were far from a "magic fix" and credits a structured diet for helping her lose two stone, the Daily Mail reported.

Started Wegovy, Mounjaro Out of 'Sheer Desperation'

Lay began taking Wegovy in late 2023 after trying several diets without success. She remained on the medication for nine months, even though she felt something "wasn't right."

“My appetite reduced slightly at first,” Lay, a financial services worker, was quoted as saying. “But not enough to make a meaningful difference, so I increased the dosage each month.”

After seeing limited results with Wegovy, Lay stopped the medication for four weeks before switching to Mounjaro. She described the transition period as experiencing the "worst food noise" and said she gained more than seven pounds while waiting for the first drug to clear from her system.

Lay then spent six months on Mounjaro but said she was "barely eating" and still failed to achieve the weight loss she expected.

“I only lost seven pounds,” she said. “I realised the injections simply weren't effective for me and something had to change.”

Her doctor eventually advised her to stop taking the medication because they were concerned she was not eating enough, the report said.

Lay said the experience was “emotionally exhausting and honestly quite soul-destroying,” and "deeply disheartening.” Watching others succeed on the drugs made it even harder.

Switched to Diet Instead

After discontinuing the injections, Lay adopted a very low-calorie diet with support from expert nutrition advisers who provided personalized guidance.

“Once the medication was fully out of my system, I began to feel genuinely better,” Lay said, adding that her “energy returned, digestion improved, and the constipation disappeared.”

Within a year, she went from a dress size 18 to size 12, the smallest she had been in 17 years, with her weight falling to 13 stone 5 pounds, the report said.

Non-responders To GLP-1 Drugs

Clinical trials have shown that most people taking these medications experience substantial weight loss.

• Wegovy: Average weight loss of about 21% after 72 weeks.
• Mounjaro: Average weight loss of about 22.5% over a similar period.

Around 2.5 million adults in the UK are estimated to be using weight-loss injections, while hundreds of thousands have signed up for the newly approved Wegovy pill, which was rolled out by the NHS this month.

But some people are 'non-responders', meaning they do not lose a meaningful amount of weight despite treatment. Research earlier this year found that around one in 10 people taking GLP-1 medications are considered non-responders.

Why Weight-Loss Drugs May Not Work For All

Although GLP-1 receptor agonists have delivered remarkable results for many people, they do not work the same way for everyone. Obesity is a complex condition influenced by brain signaling, hormones, genetics, and metabolism, meaning treatment responses can vary significantly. Possible reasons include:

• Genetic and hormonal variability
• Underlying medical conditions
• Unrealistic expectations about weight-loss outcomes

• Switching to another GLP-1 medication
• Using older, approved weight-loss medications
• Structured lifestyle changes involving diet and physical activity
• Comprehensive medical management of obesity tailored to the individual.

Oral Rehydration Solution (ORS) is one of the simplest yet most effective life-saving solutions that every household should keep readily available, doctors said on World ORS Day.

Observed every year on July 29, World ORS Day raises awareness about the importance of ORS—a scientifically formulated mix of glucose and electrolytes, including sodium and potassium—that helps prevent and treat dehydration caused by diarrhea, vomiting, fever, heat, and excessive sweating.

First introduced in 1969, ORS has transformed the treatment of dehydration worldwide. Since 2003, the World Health Organization (WHO) and UNICEF have recommended a low-osmolarity ORS formula, which improves fluid absorption and reduces the need for intravenous fluids. Today, ORS remains the gold standard for preventing and treating dehydration, particularly in children and people living in resource-limited settings.

ORS Prevents Dehydration, It Doesn't Treat the Illness

Dr. Ranjana Bhatt, Associate Director - Internal Medicine, Paras Health, Panchkula, told HealthandMe that ORS is not a medicine that cures the underlying illness but is designed to prevent and correct dehydration.

Dehydration occurs when the body loses more water and electrolytes than it takes in, most commonly due to diarrhea or vomiting. It can develop rapidly, especially in young children, older adults, and people with chronic illnesses.

Why ORS Works Better Than Water

ORS works through a well-established biological process in the small intestine. It contains the right balance of glucose and sodium, which are absorbed together through special proteins called sodium-glucose cotransporters (SGLTs). As sodium enters the bloodstream, water follows, allowing the body to rehydrate efficiently.

This mechanism makes ORS more effective than plain water—and often more effective than many commercial sports drinks—for replacing lost fluids and electrolytes quickly and safely.

"Recognizing the early signs of dehydration, such as excessive thirst, dry mouth, dizziness, reduced urination, and unusual fatigue, and starting ORS promptly can prevent serious complications. On ORS Day, we encourage every family to make ORS a household essential and use it appropriately while seeking timely medical care whenever symptoms are severe or persistent," Dr. Bhatt said.

Why Every Household Should Keep ORS

Dr. Amit Prakash Singh, Consultant - Internal Medicine, CK Birla Hospital, Delhi, told HealthandMe that ORS is one of the simplest, most affordable, and most effective ways to prevent dehydration.

"ORS is accessible for almost everyone, and the product is recommended by the World Health Organization to start treating dehydration caused by diarrhea at home. Having ORS packets at home enables treating dehydration without going to the doctor first and potentially avoiding hospitalization," he said.

When Should You Use ORS?

Besides diarrhea, ORS can help replace fluids and electrolytes lost due to:

• Fever-related dehydration
• Vomiting and gastroenteritis
• Heat exhaustion and heatstroke
• Heavy sweating after strenuous exercise
• Hangovers caused by dehydration
• Viral illnesses such as dengue
• Dehydration in older adults and people with chronic illnesses.

"ORS is not just for diarrhea. Whenever there is a lot of fluid loss or electrolyte loss, ORS can be used. ORS can be consumed for vomiting due to gastroenteritis, food poisoning, or viral infection (provided the person can sip small amounts repeatedly)," Dr. Singh said.

ORS Is Not A Cure

Doctors caution that ORS only replaces lost fluids and electrolytes—it does not treat the underlying disease.

It may help prevent dehydration after fever, vomiting, or excessive sweating, but it is not a treatment for abdominal pain, acidity, indigestion, constipation, gastritis, or irritable bowel syndrome (IBS). Persistent or severe symptoms should always be evaluated by a healthcare professional, Dr Singh said.

How To Identify Original ORS

When buying ORS, check the following:

• Look for packaging that states "WHO Recommended Formula." Any other mark or logo may not indicate a WHO-recommended ORS formulation.
• Read the label carefully. Some products may be marketed as "Ready-to-Serve Fruit Beverage" or carry a disclaimer such as: "This is only a trademark and does not represent its true nature. Not a WHO Oral Rehydration Salts." These products are not WHO-recommended ORS.
• Check the ingredients. Genuine ORS should contain glucose, sodium, and potassium in the recommended proportions.

Liver disease is unusual among serious conditions in that it can progress significantly without producing symptoms that would prompt most people to seek medical attention. Hepatitis, which is inflammation of the liver, is the most common starting point for that progression.

It may be caused by viral infections including Hepatitis B and Hepatitis C, excessive alcohol consumption, fatty liver disease, certain medications, or autoimmune conditions. In many cases, the person carrying it feels entirely well while damage accumulates over months and years.

How Chronic Inflammation Causes Lasting Liver Damage

The liver does regenerate, but that capacity has limits. When inflammation persists, healthy liver cells are progressively replaced by scar tissue, a process called fibrosis.

Continued scarring eventually produces cirrhosis, where the liver loses its structural integrity and its ability to perform the functions the body depends on it for, such as processing toxins, producing proteins involved in blood clotting, regulating metabolism, and supporting digestion. At this stage, the damage is largely irreversible.

The timeline from hepatitis to cirrhosis typically spans years or even decades, which is precisely what makes delayed diagnosis so consequential. Each year of untreated inflammation is a year of accumulated scarring.

By the time cirrhosis produces obvious symptoms such as jaundice, abdominal swelling from fluid accumulation, internal bleeding from enlarged veins in the oesophagus, cognitive changes from toxin build-up, kidney involvement, the disease has already reached an advanced stage. Cirrhosis also carries a significantly elevated risk of liver cancer.

Also read: Smoking, Diabetes, High Blood Pressure May Fuel the Most Dangerous Type of Artery Plaque, Study Finds

Early Detection Can Prevent Disease Progression

The clinical picture is meaningfully better when liver disease is identified early. Effective antiviral medications can control chronic Hepatitis B and cure most cases of Hepatitis C, substantially reducing the risk of progression.

Fatty liver disease, when caught before significant fibrosis has occurred, can often be reversed through weight management, blood sugar control, reduced alcohol intake, and consistent physical activity. These interventions are accessible, evidence-based changes that work when applied before the disease has advanced.

Screening is where early identification happens. Blood tests measuring liver enzymes and imaging studies can detect liver inflammation and early fibrosis well before symptoms appear.

For individuals with diabetes, obesity, a family history of liver disease, a history of blood transfusions, or other known risk factors, periodic liver assessment is a practical and important part of routine care rather than an optional precaution.

Also read: IIT Delhi, AIIMS Develop First Hindi Music Therapy for Stroke Patients: How Survivors Find Their Voice

Who Should Get Screened And Why It Matters

The pattern that gastroenterologists consistently encounter is patients presenting with advanced liver disease who had risk factors identifiable years earlier. Hepatitis B and C are both detectable through simple blood tests.

Fatty liver shows up clearly on ultrasound. The window for effective intervention exists, and it is considerably wider earlier in the disease than most people assume when they have never been tested.

This draws attention to a disease that carries a substantial global burden but remains widely undertreated because it does not announce itself. For anyone with known risk factors, or who has never had their liver function assessed, the appropriate response to that is a conversation with a physician, before symptoms, rather than after.

By Dr. Saswata Chatterjee, Senior Consultant – Gastroenterology, CMRI Hospital